Evotec
About: Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Employees: 4,766
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.12% more ownership
Funds ownership: 5.0% [Q4 2024] → 5.12% (+0.12%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 26 [Q4 2024] → 25 (-1) [Q1 2025]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
18% less capital invested
Capital invested by funds: $36.9M [Q4 2024] → $30.4M (-$6.53M) [Q1 2025]
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for EVO.
Financial journalist opinion
Based on 6 articles about EVO published over the past 30 days
Neutral
Accesswire
1 day ago
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.
Neutral
Accesswire
1 day ago
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with Just - Evotec Biologics remaining core business for Evotec Transaction is expected to immediately improve Evotec's short-, mid-, and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU, which owns the J.POD biologics manufacturing facility in Toulouse, France, and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license. The site has been customised and dedicated entirely to Sandoz since July 2024, and the transaction is a natural progression in an already successful partnership.
Positive
Seeking Alpha
1 week ago
Evotec: Recovery Seems To Be Beginning
Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis.
Negative
Benzinga
1 week ago
Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.
Neutral
Accesswire
1 week ago
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license revenues expected to have a stronger impactthan anticipated Significant cost optimization in excess of initial targets from Priority Reset Shared R&D base businesscontinues to navigate in a challenging market environment H1 2025 Group revenues below expectations; adj. EBITDA broadly in line with expectations Revenue guidance adjusted; R&D and adjusted EBITDA guidance unchanged, reflecting improved revenue mix and cost discipline Evotec confirms itsOutlook 2028 HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025.
Neutral
Accesswire
1 week ago
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.
Neutral
Accesswire
1 month ago
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI.
Neutral
Accesswire
2 months ago
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
Neutral
Seeking Alpha
2 months ago
Evotec SE (EVO) Q1 2025 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Conference Call Participants Christian Ehmann - Warburg Research Charles Weston - RBC Joseph Hedden - Rx Securities Fynn Scherzler - Deutsche Bank Douglas Tsao - Wainwright Brendan Smith - TD Cowen Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus Call operator.
Neutral
Accesswire
2 months ago
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy building on technology and science leadership: Focus on high-growth, high-value segments, simplifying the business model and fostering operational excellence 2025 Guidance and 2028 Outlook confirmed HAMBURG, DE / ACCESS Newswire / May 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to generate sustainable profitable growth. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "With € 200 m of revenues we ended Q1 2025 slightly ahead of our expectation, despite a soft drug discovery market environment.
Charts implemented using Lightweight Charts™